Conservative Management of Endometrial Cancer: A Survey Amongst European Clinicians

dc.contributor.authorLa Russa, M.
dc.contributor.authorZapardiel, I.
dc.contributor.authorHalaska, M. J.
dc.contributor.authorZalewski, K.
dc.contributor.authorLaky, R.
dc.contributor.authorDursun, P.
dc.contributor.authorLindquist, D.
dc.contributor.authorSukhin, V.
dc.contributor.authorPolterauer, S.
dc.contributor.authorBiliatis, I.
dc.contributor.pubmedID29943129en_US
dc.date.accessioned2023-04-24T11:58:42Z
dc.date.available2023-04-24T11:58:42Z
dc.date.issued2018
dc.description.abstractTo investigate differences and similarities in the clinical approach of young clinicians managing women with endometrial cancer (EC) conservatively. A web-based survey was carried out. A platform of the European Network of Young Gynaecological Oncologists (ENYGO) database was used. A 38-item multiple-choice questionnaire was used to evaluate current practice in fertility-sparing management of EC. The survey covered investigations, treatment options, follow-up and management of recurrence and future family planning. Descriptive statistics were used. Overall, 116 out of 650 (17.84%) ENYGO members responded to the survey. In 92 (79.3%) centres, the caseload of early stage EC treated conservatively was less than 10 per year. One hundred and seven responders (93.8%) believe that treatment with progestins could be offered in grade 1 EC without myometrial invasion, but a minority would recommend it even for grade 2 tumours with no myometrial invasion or grade 1 with superficial invasion. The diagnostic tool for establishing grade of tumour was hysteroscopy with dilatation and curettage in 64 (55%) centres. Medroxyprogesterone acetate represents the most commonly prescribed progestogen (55, 47.4%). In 78 (67.2%) centres, a repeat endometrial biopsy was offered after 3 months of treatment commencement. Recurrences are treated mostly with hysterectomy (81, 69.9%) with only a small number of responders recommending to repeat progestin treatment. Lynch syndrome is a contraindication for conservative management in half of the responders (57, 49.1%). Most clinicians agree that patients should be referred promptly for assisted reproductive techniques once complete response has been achieved (68, 58.6%). Our study shows that conservative management is increasingly offered to women affected by early stage EC wishing to preserve their fertility. Further studies and joint registries are required to evaluate safety and effectiveness of this approach in this probably growing number of patients.en_US
dc.identifier.endpage380en_US
dc.identifier.issn0932-0067en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85049111053en_US
dc.identifier.startpage373en_US
dc.identifier.urihttp://hdl.handle.net/11727/8858
dc.identifier.volume298en_US
dc.identifier.wos000438090000016en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s00404-018-4820-7en_US
dc.relation.journalARCHIVES OF GYNECOLOGY AND OBSTETRICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial canceren_US
dc.subjectConservative managementen_US
dc.subjectProgestinsen_US
dc.subjectAssisted reproductionen_US
dc.subjectPregnanciesen_US
dc.titleConservative Management of Endometrial Cancer: A Survey Amongst European Cliniciansen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: